Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents
- 1 February 2010
- journal article
- review article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 10 (1), 64-73
- https://doi.org/10.3816/cbc.2010.n.009
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast CancerClinical Cancer Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline ChemotherapyJournal of Clinical Oncology, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJama-Journal Of The American Medical Association, 2006
- Surgery for liver metastases from breast cancerHPB, 2006
- Albumin-Bound PaclitaxelDrugs, 2006
- Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenBreast Cancer Research and Treatment, 2005
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerEuropean Journal Of Cancer, 2004
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal of Cancer, 1996